CD19 and acute lymphoblastic leukemia: The FDA approved CAR T-cells directed against CD19 [CD19+ CAR T-cells; tisagenlecleucel (KymriahTM, Novartis)] in August 2017 to treat acute lymphoblastic leukemia (ALL) and then axicabtagene ciloleucel (YescartaTM, Kite Pharma) for the treatment of R/R large B-cell lymphoma in October 2017 [19, 20].